M. Kooshyar

Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).

E. Wattel, H. Rahimi, A. Shirdel, 2009, Blood.

The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma

A. Ghavamzadeh, H. Rahimi, A. Shirdel, 2013, Retrovirology.

Clinical Trials and Observations

E. Wattel, H. Rahimi, A. Shirdel, 2006 .

Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran

A. Shirdel, H. Rafatpanah, M. Mahmoudi, 2007, Leukemia & lymphoma.

The combination of arsenic, interferon-alpha, and zidovudine restores an “immunocompetent-like” cytokine expression profile in patients with adult T-cell leukemia lymphoma

A. Ghavamzadeh, H. Rahimi, A. Shirdel, 2013, Retrovirology.

Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia-lymphoma (ATL)

E. Wattel, H. Rahimi, A. Shirdel, 2009 .

Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).

E. Wattel, H. Rahimi, A. Shirdel, 2009, Blood.